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Cystic ﬁbrosis (CF) is a monogenic disease caused by mutations in the CF transmembrane conductance regulator (CFTR) gene,
withlungandlivermanifestations.Becauseofpitfallsofgenetherapy,novelapproachesforreconstitutionoftheairwayepithelium
and CFTR expression should be explored. In the present study, human amniotic mesenchymal stem cells (hAMSCs) were isolated
from term placentas and characterized for expression of phenotypic and pluripotency markers, and for diﬀerentiation potential
towards mesoderm (osteogenic and adipogenic) lineages. Moreover, hAMSCs were induced to diﬀerentiate into hepatocyte-like
cells, as demonstrated by mixed function oxidase activity and expression of albumin, alpha1-antitrypsin, and CK19. We also
investigated the CFTR expression in hAMSCs upon isolation and in coculture with CF airway epithelial cells. Freshly isolated
hAMSCs displayed low levels of CFTR mRNA, which even decreased with culture passages. Following staining with the vital
dye CM-DiI, hAMSCs were mixed with CFBE41o- respiratory epithelial cells and seeded onto permeable ﬁlters. Flow cytometry
demonstrated that 33–50% of hAMSCs acquired a detectable CFTR expression on the apical membrane, a result conﬁrmed by
confocal microscopy. Our data show that amniotic MSCs have the potential to diﬀerentiate into epithelial cells of organs relevant
in CF pathogenesis and may contribute to partial correction of the CF phenotype.
1.Introduction
Human placenta may represent a fruitful reserve of stem cells
for regenerative medicine. Amniotic epithelial cells (hAECs)
and amniotic mesenchymal stromal cells (hAMSCs) are
known to have unique characteristics, such as derivation
from early embryological development, low level expression
of major histocompatibility complex antigens, and a less-
restricted diﬀerentiation potential [1]. In culture, hAECs
and hAMSCs can diﬀerentiate toward “classic” mesodermal
lineages (osteogenic, chondrogenic, and adipogenic), as well
as toward cell types of all three germ layers-ectoderm, meso-
derm, and endoderm (reviewed in [2, 3]). Because the amni-
otic membrane is discarded after delivery, it is easy to obtain
without harming mothers or babies and would thereby over-
come the ethical issues associated with the use of embryonic
stem cells. Based on these considerations, human amniotic
membrane/amnion-derived cells are considered to be a use-
ful biological material and also a novel cell source for cell
transplantation. The availability of hAECs and hAMSCs and2 Journal of Biomedicine and Biotechnology
the lack of ethical concerns for this source of stem cells are
consideredadvantageousfortheirwidespreaduseandaccep-
tance.
Cystic ﬁbrosis (CF) is a lethal autosomal recessive disor-
der due to mutations in the CF transmembrane conductance
regulator (CFTR) gene, a cAMP-dependent chloride channel
expressed on the apical side of epithelial cells [4]. Although
CF involves many organs with secretory/absorptive proper-
ties, including the liver, the main cause of morbidity and
mortality is a chronic inﬂammatory lung disease. Because of
its monogenic nature, and since the lung is easily accessible,
CFhasbeenatargetdiseaseforgene-basedtherapeuticinter-
vention; however, this approach has given unsatisﬁed results
in terms of eﬃciency of gene delivery to the lung and of eﬃ-
cacy outcomes [5]. This partial success was due to the inef-
ﬁciency of passing the mucus barrier overlying the epithelial
cells and to the immune response against the gene therapy
vectors [6]. Cell therapy could be a more eﬀective treatment
because allogenic normal cells and autologous engineered
cells express CFTR gene. Bone marrow-derived stem cells
have been the ﬁrst source evaluated for homing to the lung
andcurativepotential,buttheinvivoeﬃciencyofbonemar-
row stem cells to diﬀerentiate in airways epithelium is very
low (0.01–0.025%) [7], as also demonstrated by diﬀerent
studies in CF mice [8, 9].
Recently, new cell sources for CF treatment have been
characterized; MSCs from cord blood [10] and amniotic
ﬂuid stem cells [11]c a nd i ﬀerentiate in vitro and in vivo in
airway epithelium. Stemming from these results on MSCs,
and based on the demonstrated high plasticity of amniotic-
derived stem cells, after an extensive characterization of
the expression of phenotypic and pluripotency markers by
hAMSCs and their diﬀerentiative potential, we preliminarily
evaluatedtheirusefulnessinCFbyinvitroexperimentsusing
cocultures of hAMSCs and CF-respiratory epithelial cells.
2.MaterialsandMethods
2.1. Isolation and Culture of Human Amniotic Mesenchymal
Stromal Cells. Human amniotic mesenchymal stromal cells
(hAMSCs) were isolated from term placentas (n = 3) which
would normally be discarded after delivery. Tissues were
obtained under appropriate Ethical Committee approval and
signed informed consent. All infectious pathogen-positive
deliveries including those involving HBV, HCV, and HIV,
as well as cases of prediagnosed genetic abnormalities, were
excluded. Placenta samples were procured immediately after
deliveryandprocessedundersterileconditions.Afterpeeling
from the placenta and washing with calcium- and magnesi-
um-free HBSS (CMF-HBSS, Lonza, Treviglio, Italy) supple-
mented with 0.5mM EGTA (Sigma, Milan, Italy), amnion
m e m b r a n e sw e r ep r o c e s s e dt or e m o v ee p i t h e l i a lc e l l sa sp r e -
viously reported [12]. Once epithelial cells were removed,
the amniotic membranes were digested in order to collect
hAMSCs [13]. Brieﬂy, amniotic membranes were washed
three times with cold HBSS, cut into pieces, and transferred
into 50-mL centrifuge tubes, containing about 30–40mL of
digestion solution composed by EMEM (Lonza) supple-
mented with 25mM HEPES buﬀer without L-glutamine
(Lonza),1mg/mLcollagenasetypeIV,and25μg/mLDNaseI
(both from Sigma, Milan, Italy). Membranes were incubated
on a rotator between 45min to 1.5h, depending on tissue
thickness, at 37◦C. After blocking the enzymatic reaction
withcoldHBSS,cellsuspensionswerecentrifuged2timesfor
5min at 200×g, 4◦C and counted using a B¨ urker chamber.
After isolation, DNA was obtained from hAMSCs and
hAECs by phenol/chlorophorm extraction. Puriﬁed DNA
was investigated for most frequent mutations in CFTR gene
using a commercial kit (Inno-Lipa CFTR19, Inno-Lipa
CFTR17+TnUpdate, Inno-Lipa CFTR-Italian Regional-
Innogenetics, Ghent, Belgium).
hAMSCs were plated at a density of 1 ×105 cells per cm2
in standard culture medium composed by DMEM (Lonza)
supplemented with 1% sodium pyruvate, 10% (v/v) heat-
inactivatedfetalbovineserum(FBS),1%nonessentialamino
acid, 55μM β-mercaptoethanol (all by Invitrogen, Milan,
Italy), 1% L-glutamine, 1% antibiotics solution (both by
Cellgro, Manassas, VA, USA), and 10ng/mL epidermal
growth factor (EGF, Sigma), according to the previously
reported protocol [13]. Medium was replaced 2h after plat-
ing in order to remove unattached contaminating epithelial
cells and then every 2 days.
Every time cells reached 80% of conﬂuence, cells were
detached with trypsin-EDTA (Invitrogen), washed, counted
with a B¨ urker chamber, and replated in a new plastic ﬂask at
a density of 1 × 105 cells per cm2 in order to calculate their
growth curve. Doubling time was calculated inserting times
and cell counts on the website http://www.doubling-time
.com/compute.php.
2.2. Characterization of hAMSCs
2.2.1. Flow Cytometry. Flow cytometry analyses of hAMSCs
wereperformedimmediatelyafterdissociationandatsecond
culture passage as previously described [14]. Brieﬂy, cells
were detached from culture ﬂask using trypsin and, after
washing,wereincubatedwith4%normalmouseserum/PBS/
NaN3 for 20 minutes at 4◦C in order to block nonspeciﬁc
sites on cell membrane. Cells were then stained in the dark at
4◦C for 20 minutes with 7-amino actinomycin-D (7AAD) to
discriminate viable cells from fragments and dead cells and
with the following monoclonal antibodies (moabs): against
CD13, CD29, CD31, CD34, CD44, CD45, CD49f, CD73,
CD90, CD105, CD146, CD166, EpCAM, SSEA4 (all from
BectonDickinsonBiosciences,BD,FranklinLakes,NJ,USA),
and CD133-1 (Miltenyi Biotech, Bergisch Gladbach, Ger-
many). Moabs were conjugated with ﬂuorescein isothiocya-
nate (FITC) or phycoerythrin (PE) or PE-Cyanin 7 (PE-Cy7)
or allophycocyanin (APC) or APC-Cyanin 7 (APC-Cy7).
For internal labelling, cells were ﬁxed at room tempera-
ture with 4% paraformaldehyde (PFA) for 10min and per-
meated with 100% ethanol for 2min after washing with PBS.
Cells were incubated with 10% FBS to block nonspeciﬁc
binding, followed by primary antibodies against Oct-4 and
Nanog(SantaCruzBiotechnology, SantaCruz,CA,USA)for
1h; secondary PE-conjugated antibody (Invitrogen) was ap-
plied for 30min. The ﬂuorescence threshold between nega-
tive and positive cells was set on the basis of the reactivity ofJournal of Biomedicine and Biotechnology 3
appropriate nonspeciﬁc ﬂuorochrome-conjugated isotypic
controls. At least, 106 cells were ﬁnally analysed using a
FACSCanto II equipped with FACSDiva software (BD).
2.2.2. Immunoﬂuorescence Microscopy of Cultured Cells. Plat-
ed cells were stained as reported elsewhere [14]. Fixed (4%
PFA or 70% ethanol for 30min) and permeabilized (HEPES-
Triton X-100 buﬀer 0.25% in PBS for 20min) cells were in-
cubated with a blocking buﬀer containing 0.5M NaCl,
20mM NaHPO4, 0.1% Triton X-100, and 30% horse and
goat serum for 30min (all reagents were from Sigma) and
then immunostained with the following primary moabs:
anti-EpCAM,cytokeratin(CK)18,alpha-fetoprotein(Sigma),
CK19 (Novocastra, Newcastle, UK), albumin (DakoCyto-
mation, Milan, Italy), CK7, CD49f, CD29, S100A4, CD90,
CD31, CD146, zonula occludens-1 (ZO-1), ﬁbronectin, al-
pha1-antitrypsin, E-cadherin, and beta-catenin (BD) for 2h.
After washing, cells were incubated with the appropriate sec-
ondary FITC or Texas Red-conjugated antibodies (BD) for
1h in the dark. Nuclei were counterstained with 4 ,6-diami-
dino-2-phenylindole (DAPI, Sigma) for 5min in the dark.
Images were taken using a Leica Microsystems DM IRE 2
microscope and analysed with the FW4000I software (Leica
Microsystems, Milan, Italy).
2.2.3. Reverse-Transcriptase (RT)-Polymerase Chain Reaction
(PCR). CFTR mRNA expression was investigated by semi-
quantitative RT-PCR. Total RNA was isolated from freshly
isolated and cultured cells with TRIzol Reagent (Invitro-
gen), according to the manufacturer’s protocol. One μgo f
RNA was reverse transcribed into ﬁrst strand cDNA with
the High-Capacity cDNA Reverse Transcription kit (Applied
Biosystems) using random primers following manufacturer’s
instructions. In order to analyze the expression of CFTR
gene, 100ng of cDNA was used in a ﬁnal volume of 25μL
with 200nM dNTP, 10pM of each outer primer (Table 1),
0.3U Taq-DNA-polymerase, reaction buﬀer, and MgCl2 (In-
vitrogen). A second nested PCR was performed using inner
primers (Table 1). Cycling conditions consisted of 95◦Cf o r
30 seconds, annealing at 60◦C for 1min and elongation at
72◦C for 2min. Cycle numbers consisted of 35 cycles. cDNA
from nasal brushing from healthy control was used as posi-
tivecontrolforCFTRanalysis;noreverse-transcribedsample
w a su s e da sn e g a t i v ec o n t r o l .
In parallel, β-actin was used as house-keeping gene
(Table 1). PCR products were evaluated on 1.5% agarose gel
electrophoresis.
2.3. Diﬀerentiation of hAMSCs Towards Diﬀerent Lineages
2.3.1. Adipogenic and Osteogenic Diﬀerentiation. To induce
adipogenicandosteogenicdiﬀerentiation,cellsatpassages1–
3 were harvested and plated on tissue culture dishes (BD) at
a density of 4×103 cells per cm2. Cells werethentreatedwith
either adipogenic or osteogenic diﬀerentiation media (Lonz-
a) for three weeks. The adipogenic protocol consisted of 4
rounds of adipogenic induction medium for 2 days followed
byadipogenic maintenancemediumfor3days.Thepresence
of adipose elements in induced cultures was determined by
Oil-Red-O (Sigma) staining as follow: cells were washed in
PBS, then ﬁxed in 10% formalin for 1h, washed in isopro-
panol60%,andairdried.CellswerethenincubatedwithOil-
Red-O staining solution for 10min, then washed several
times in PBS, and observed with an inverted microscope
EclipseTS100(Nikon,Tokyo,Japan)equippedwithaDS-FI1
CCD camera (Nikon).
In order to induce osteogenesis, cells were treated with
osteogenic medium for 3 weeks with medium changes 3
times a week. The presence of calcium deposits in induced
cultures was determined by Alizarin Red (Sigma) staining
as follow: cells were ﬁxed in 10% formalin for 1h, then
washedindeionizedwater,andincubatedfor30minatroom
temperature with Alizarin Red 2% in water at pH 4.2. The
cells were ﬁnally washed several times to remove the excess
of staining and analyzed as described above.
2.3.2. Hepatocyte Diﬀerentiation. A simple protocol [15]w a s
used for hepatic diﬀerentiation of hAMSCs; cells were plated
on type 1 collagen-coated culture dishes in DMEM supple-
mented with 10% FBS, 1% nonessential aminoacids, 1% L-
glutamine, beta-mercaptoethanol, and 10ng/mL of EGF for
8 days and then with IMDM with the same compounds plus
10−7 M dexamethasone (Sigma) for 6 days. One of the func-
tions in cultured hepatocytes is that of the cytochrome P450-
dependent mixed function oxidases (MFOs). Diethoxy (5,6)
chloromethylﬂuorescein (Invitrogen) is a probe suitable for
use as an in situ stain for MFO activity since this colorless
molecule is metabolized in a ﬂuorescent green compound
retained in the cells [16]. Five mg of probe was eluted in
1143μLD M S O( s t o c ks o l u t i o n1 0m m o l ) .T e s tm e d i u mw a s
prepared as follow: 987μLo fR P M I ,1 2 μL HEPES 1M
(12mmol ﬁnal), and 1μL probe 10mmol (10μmol ﬁnal).
Controlmediumwaspreparedasfollow:987μLRPMI,12μL
HEPES 1M (12mmol ﬁnal), and 1μLD M S O .T h ec e l l sw e r e
washed in PBS and incubated with the test (or control) med-
ium for 2h at 37◦Ci naC O 2 incubator. Cells were analyzed
using a Leica Microsystems DM IRE 2 microscope.
After diﬀerentiation for 21 days (8 days in DMEM sup-
plemented as above +13 days in IMDM supplemented with
dexamethasone), cells were stained by means of immunoﬂu-
orescence as reported above in order to verify the expression
of epithelial markers.
2.4. hAMSC Labelling. Passage two hAMSCs were labeled
with chloromethylbenzamido (CellTracker CM-DiI) [17].
Stock solutions of CM-DiI were prepared in dimethylsulfox-
ide (DMSO) at 1ng/μL. Immediately before labelling, the
stock solution was diluted up to a ﬁnal concentration of
0.005ng/μL in DMEM without phenol red. Cells grown at
conﬂuence in a T25 ﬂask were washed with phosphate-buﬀ-
ered saline (PBS) and then incubated with the dye working
solution for 30min at 37◦C. After labelling, cells are washed
twice with PBS, then incubated at 37◦C5 %C O 2 for at least
24h in the presence of fresh medium.4 Journal of Biomedicine and Biotechnology
Table 1: Primer sequences for CFTR RT-PCR analysis.
Gene Forward primer Reverse primer Product length (bp)
CFTR
Outer primers CGAGAGACCATGCAGAGGTC GCTCCAAGAGAGTCATACCA 1108
Inner primers CGAGAGACCATGCAGAGGTC TGTACTGCTTTGGTGACTTCCCC 301
β-actin CAACTGGGACGACATGGA ACGTCACACTTCATGATGGA 610
2.5. Cultures of Airway Epithelial Cells. 16HBE14o- and
CFBE41o-arehumanepithelialbronchialcelllines,wildtype
and homozygous for the F508del allele (F508del/F508del),
respectively, a generous gift of Professor D. Gruenert (Uni-
versity of California at San Francisco, USA). Epithelial cells
were grown in MEM, 10% FBS, 100U/mL penicillin, and
100U/mL streptomycin, alone or in Coculture with hAM-
SCs.
2.6. Coculture of hAMSCs with CFBE41o- Cells. Labelled
hAMSCs were mixed with CFBE41o- cells at diﬀerent ratios
(1:5, 1:10, 1:15, and 1:20) and, in order to obtain polar-
ized cocultures, cells were seeded on 6.5-mm diameter Snap-
well, 0.4-μm pore size (Corning, Acton, MA, USA) at 1×105
per ﬁlter coated with a solution of 10μg/mL ﬁbronectin (BD
Biosciences, CA, USA), 100μg/mL albumin from bovine
serum (Sigma-Aldrich, Milan, Italy), and 30μg/mL bovine
collagentypeI(BD)dissolvedinMEM.Ascontrols,hAMSCs
and CFBE41o- were seeded at 2.5×104 and 1×105 per ﬁlter,
respectively.Coculturesweremaintainedat37◦C5%CO 2 for
at least 6–8 days.
Separate cocultures were obtained by seeding hAMSCs
onto the ﬁlter and CFBE41o- cells onto the bottom of the
lowerchamber.Toobtain1:5and1:10ratios,hAMSCswere
seeded at 2 × 104 and 1 × 104 and CFBE41o- cells at 8 × 104
and9×104,respectively.Ascontrols,hAMSCswereseededat
1×105 perﬁlter.Mediumwaschangeddailyineachchamber
for 5 days, and cultures were analyzed at day 6.
2.7. CFTR Cytoﬂuorimetric Assay. C e l l sw e r ed e t a c h e dw i t h
trypsin-EDTA treatment and ﬁxed in PBS containing 2%
PFA for 5min. After centrifugation at 250×g, the resulting
pellets were washed and resuspended in PBS. The cells
were then incubated with CFTR antibody MAB25031 mouse
IgG2a (R&D Systems, Minneapolis, MN, USA) used at 1:20
dilution for 1h at 4◦C. After washing in PBS, the cells were
incubated with the FITC-conjugated secondary antibody
(anti-mouse used at 1:100; Sigma) for 1h at 4◦C, followed
by two washes in PBS, and analyzed. As a background con-
trol, cocultures were incubated with secondary antibody
only, and the resulting ﬂuorescence was subtracted from the
analyzed samples incubated both with primary and second-
ary antibodies. Data were collected using a Coulter Epix XL
ﬂow cytometer (Beckman Coulter, Fullerton, CA, USA) and
analyzed with WinMDI 2.9 (http://www.cyto.purdue.edu/
ﬂowcyt/software/Winmdi.htm). Ten thousand cells were ex-
amined in each experiment. Since physical parameters (for-
ward scatter and side scatter) did not allow us to distinguish
hAMSCs from CFBE41o- cells, speciﬁc expression of CFTR
on hAMSCs was detected in the CM-DiI-labelled cells. Anal-
yseswereperformedbyplottingtheFLH-1channel(525nm)
against the FLH-2 channel (575nm), identifying the CFTR-
speciﬁc green signal and the red-labelled hAMSCs, respec-
tively. The vitality was evaluated by trypan blue exclusion as-
say and resulted to be >98%.
2.8. Confocal Analysis of CFTR Protein. Polarized cells were
washed three times with PBS and incubated in PBS, 2% BSA
for 30min on ice. Cells were incubated with CFTR anti-
body MAB25031 diluted 1:20 in PBS containing 0.2% BSA
for 1h on ice. Cells were rinsed three times with PBS and
incubated withtheFITC-conjugatedsecondaryantibody dil-
uted 1:100 in PBS added with 0.2% BSA for 30min on ice.
After two washes in PBS, cells were ﬁxed in 3% PFA and 2%
sucrose for 10min. After three washes in PBS, ﬁlters were
excised and placed side up on a glass slide and overlaid with
adropofMowiol(Calbiochem,SanDiego,CA,USA)follow-
ed by a coverslip. Cells were analyzed using a Nikon TE2000
microscope coupled to a Radiance 2100 confocal dual-laser
scanning microscopy system (Bio-Rad, Segrate, Italy). Spec-
imens were viewed through a 60x oil immersion objective.
DigitalimageswereprocessedusingtheprogramLaserSharp
2000 (Bio-Rad).
2.9. Statistical Analysis. Statistical signiﬁcance of diﬀerences
was evaluated by a two-tailed unpaired Student’s t-test. Data
were analyzed using Prism 4 (GraphPad Software, Inc., La
Jolla, CA, USA). P values of less than 0.05 were considered
signiﬁcant.
3. Results
3.1. Isolation and Characterization of hAMSCs from Human
Amnion. At least 33 × 106 hAMSCs (range 26–160 × 106)
were recovered in each isolation (n = 3) with a viability of
85–90%. Inno-lipa screening revealed the absence of most
frequent mutation of CFTR (86% of detection rate) in
hAMSCs used in this study. After plastic adhesion, hAMSCs
were characterized by a ﬁbroblastic morphology very similar
to that described for mesenchymal cells isolated from bone
marrow (Figures 1(a) and 1(b)) and could be kept in culture
until passages 5–10. Proliferation slowed beyond passage
two. In the exponential growth phase, approximately two cell
doublings were observed over 15 days, giving these cells an
average doubling time of 18.03 days calculated over 28 days
of culture. An example of a growth curve for hAMSCs is
presented in Figure 1(c).Journal of Biomedicine and Biotechnology 5
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Figure 1: hAMSCs morphology and growth. Cell morphology at passage one (a) and passage three (b), original magniﬁcation 10x. Growth
kinetics of hAMSCs in culture (c).
3.2.FlowCytometryandImmunoﬂuorescenceAnalysis. hAM-
SCs showed an immunophenotypic proﬁle very similar to
that of mesenchymal stem cells derived from bone marrow;
that is, they are positive for CD29, CD44, CD73, CD90,
and CD105 and negative for the hematopoietic markers
CD34, CD133, and CD45. Freshly isolated hAMSCs showed
a low expression of epithelial markers (EpCAM and CD49f),
which decreased up to null expression after the ﬁrst passage
(Table 2).
hAMSCs showed the embryonic stem cell associated sur-
face marker SSEA4 (Figure 2(f)), while very low expression
of molecular markers associated with pluripotent stem cells
(Nanog and Oct-4) by ﬂow cytometry was observed (Figures
2(d) and 2(e)).
Fluorescence microscopy conﬁrmed the positivity for
CD29andCD90andrevealedtheexpressionofothermesen-
chymal markers such as ﬁbronectin and vimentin (Figure 3).
hAMSCs were almost negative for ZO-1, a marker of tight
junctions and cytokeratin (CK) 7, while stained positive for
CK18.
3.3. Cell Diﬀerentiation Ability. To determine whether hAM-
SCs could diﬀerentiate into adipocytes, cells were allowed to
grow to 70% conﬂuence prior to induction. Morphological
changes as well as formation of lipid droplets within the cells
were noticeable starting from one week after induction and
were visualized by Oil-Red-O staining (Figure 4(b)). Cells
maintained in control medium did not show any sign of adi-
pogenic diﬀerentiation (Figure 4(a)).
To investigate the osteogenic potential of hAMSCs, cells
were cultured under appropriate condition for diﬀerentia-
tion. The presence of calcium deposits in induced cultures
was determined by Alizarin Red (Figure 4(d)). Cells main-
tained in control media did not show any change in their
morphology and no calcium deposit (Figure 4(c)).
Hepatocyte diﬀerentiation of hAMSCs was evaluated
after 14 days of induction. Cells were incubated for 2h with
diethoxy (5,6) chloromethylﬂuorescein. The generation of
ﬂuorescent products was evaluated by ﬂuorescence micro-
scopy. Although hAMSCs were of mesenchymal origin, they
showed signs of hepatocyte diﬀerentiation (Figure 4(f)).
Cells maintained in control medium did not show any sign
of hepatocyte diﬀerentiation (Figure 4(e)).
Moreover, we performed cell immunophenotyping after
hepatocyte induction (Figure 5). After hepatocyte differenti-
ation, the number of cells expressing CK7 increased, while
some cells expressed albumin and, weakly, alpha1-antitryp-
sin. Finally, we observed also the presence of CK19- positive
cells. No alpha-fetoprotein expression was detected (not
shown).
3.4. CFTR mRNA Expression. In order to see whether
hAMSCs express CFTR mRNA, a semiquantitative RT-PCR6 Journal of Biomedicine and Biotechnology
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Figure 2: hAMSCs pluripotent stem cells and ESC marker expression. Flow cytometry representative expression of the pluripotent and
embryonic stem cells markers in freshly isolated hAMSCs. (a) For each staining, a gate on viable cells (red) was drawn; (b) hAMSCs were
gated on the basis of morphological features; (c) cells incubated with isotypic control were used as negative controls; (d) Nanog, (e) Oct-4,
and (f) SSEA4 expression in hAMSCs.
Table 2: hAMSCs membrane marker expression.
Surface antigens
Freshly isolated Passage two
Median % Range Median % Range
CD45 2 0–4 4 3-4
C D 3 4 00 - 100 - 1
C D 1 3 3 00 - 100 - 1
CD13 80 70–89 95 89–99
CD44 81 71–90 90 89–92
CD73 90 88–91 94 88–99
CD90 79 69–89 94 89–99
CD29 76 66–86 98 95–99
CD105 49 30–66 58 40–76
CD166 83 71–95 85 71–98
CD49f 16 13–31 3 2–5
EpCAM 16 12–20 0 0-1
CD31 0 0 ND ND
CD146 0 0 ND ND
Data were expressed as median percentage and ranges of three diﬀerent experiments.
assay was carried out. CFTR was detected in hAMSCs by
RT-PCR only after nested PCR (Figure 6). The expression of
CFTR in hAMSC appeared to decrease dramatically during
culture. hAECs showed a similar expression of CFTR mRNA
when studied upon isolation (Figure 6).
3.5. CFTR Protein Expression by Flow Cytometry. hAMSCs
stained with CM-DiI (as described in Materials and Methods
section)weremixed withCFBE41o- cellsatdiﬀerent increas-
ing ratios (1:20, 1:15, 1:10, and 1:5) and seeded onto
semipermeable ﬁlters. In order to analyze the CFTR proteinJournal of Biomedicine and Biotechnology 7
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Figure 3: Immunoﬂuorescence characterization of hAMSCs. Representative images of ﬂuorescence microscopy staining. The upper left
panel (denoted as “negative”) shows cells incubated with the secondary antibody only. hAMSCs were positive for CD29, CD90, ﬁbronectin,
vimentin, and CK 18 and negative for ZO-1 and CK 7. Nuclei were counterstained with DAPI. Original magniﬁcation 20x.
expression in hAMSC–CFBE41o- cocultures at diﬀerent ra-
tios,aﬂowcytometricassaywasperformed.Thismixedpop-
ulation was analyzed after labelling with the CFTR antibody
MAB25031intheabsenceofpermeabilizationfollowedbyan
incubation with FITC-conjugated secondary antibody. As a
positive control, CFTR labelling was assessed in normal
human airway 16HBE14o- cells, resulting in 50 ± 5.0% of
positive cells, as previously shown [18]. CFBE41o- cells
showed less CFTR-speciﬁc labelling on the membrane (11%
of positive cells), consistent with the lack of CFTR transport
on the plasma membrane which is a characteristic of these
cells. Plasma membrane CFTR expression was detected in8 Journal of Biomedicine and Biotechnology
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(c) (d)
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Figure 4: In vitro diﬀerentiation capability. Representative images of in vitro osteocyte (b), adipocyte (d), and hepatocyte (f) diﬀerentiation
of hAMSCs. (a), (c), and (e) represent respective negative controls (i.e., uninduced cells). Original magniﬁcation 20x.
only 6.2% of hAMSCs (Table 3). It was possible to detect an
increaseofCFTR-speciﬁcsignalinCM-DiI-labeledcellsatall
hAMSC–CFBE41o- ratios as compared with hAMSCs cells
alone. The lower the ratio of hAMSCs:CFBE41o- the lower
the increase in CFTR-speciﬁc signal in CM-DiI-labeled cells,
thesedataindicatingthatacriticalnumberofhAMSCsisim-
portant in order to obtain a meaningful eﬀect on CFTR
expression. Overall, these data show that a population of
hAMSCs with low CFTR expression have increased this ex-
pression upon cocultures with CF epithelial cells.
To investigate the mechanism underlying the expression
ofCFTRinhAMSCsaftercocultureswithCFBE41o-cells,we
performed separate cocultures of hAMSCs and CFBE41o-
cells. Thus, hAMSCs were grown onto the ﬁlter whereas
CFBE41o- cells were seeded onto the bottom well. After 6
days of culture, hAMSCs were analyzed for CFTR expression
by cytoﬂuorimetry. Results showed that, at the hAMSCs:
CFBE41o- ratios of 1:5 and 1:10, the percentages of CFTR+
hAMSCs were 10.5±3.8a n d1 1 .6±5.0, respectively (n = 3).
These data, compared with those obtained in direct Cocul-
ture conditions (column “% of CFTR+ in whole CM-DiI+
population” of Table 3), indicate that a direct contact be-
tween hAMSCs and CFBE41o- is necessary to obtain a signi-
ﬁcant increase of CFTR-speciﬁc signal in hAMSCs.
3.6. CFTR Expression and Localization by Confocal Microsco-
py. To conﬁrm cytoﬂuorimetric data and to analyze CFTR
expression in cell compartments, hAMSC–CFBE41o- cocul-
t u r e sw e r ea s s a y e db ym e a n so fc o n f o c a lm i c r o s c o p y .I n
previously published work [19], we showed that CFTR pro-
tein is expressed on the apical side of 16HBE14o-cells, whileJournal of Biomedicine and Biotechnology 9
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Figure 5: Immunophenotype of mesenchymal stem cells prior (left) and after (right) hepatocyte diﬀerentiation for 21 days. (a–f) negative
controls, (b–g) CK7, (c–h) albumin, (d–i) alpha1-antitrypsin, and (e–j) CK19. Original magniﬁcation 20x. The insert h1 represents an
enlargement of the cell highlighted by the white square.10 Journal of Biomedicine and Biotechnology
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M T0 P1 P3 Ctr− Ctr+
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610 bp
Figure 6: CFTR mRNA expression in hAMSCs and hAECs. CFTR on hAMSCs and hAECs upon isolation (T0) and on hAMSCs at passages
one (P1) and three (P3). Upper panels: CFTR; lower panels: β-actin. M: molecular weight markers; Ctr+: positive control (nasal brushing);
Ctr−: negative control (no RT). On the right, arrows indicate the speciﬁc band along with PCR-product length.
Table 3: Percentages of CFTR+ hMSCs labelled with CM-DiI in cocultures with CFBE41o- cells.
%o fC M - D i I + CFTR+ cells % of CFTR+ in whole CM-DiI+ population P
hAMSCs — 6.2 ±2.0—
CFBE — 11.2 ±1.3 0.0006
hAMSC-CFBE 1:5 12.1 ±2.55 0 .0 ±6.1 <0.0001
hAMSC-CFBE 1:10 7.5 ±2.14 6 .7 ±9.3 <0.0001
hAMSC-CFBE 1:15 3.0 ±0.43 3 .2 ±6.5 <0.0001
hAMSC-CFBE 1:20 2.2 ±0.93 4 .6 ±8.7 <0.0001
Percentages of CM-DiI+CFTR+ cells were obtained by plotting the FLH-1 channel, identifying CFTR-speciﬁc green signal, against FLH-2 channel, identifying
red-labelled hAMSCs. Percentages of CFTR-expressing hAMSCs in whole CM-DiI+ population were obtained by dividing the double positive hAMSCs for all
CM-DiI+ cells (with and without green signal). Data are shown as the mean ± SD of ﬁve experiments. Signiﬁcance is referred to CFTR+ cells in the whole
CM-DiI+ population in all conditions as compared with hMSCs alone.
CFBE41o- cells display only intracellular staining. CFTR
expression and localization was evaluated by epiﬂuorescence
with a protocol which allows to detect only surface and not
intracellular CFTR (see Materials and Methods section), fol-
lowed by confocal microscopy analysis. As can be seen in
Figure 7, CFTR was highly expressed on the apical mem-
brane of some hAMSCs since red labelled cells showed
a green staining at membrane level (Figures 7(b)–7(d)),
whereas CFBE41o- monolayers in absence of hAMSCs
showed essentially no speciﬁc signal for CFTR expression
on the membrane (Figure 7(a)), consistent with the lack of
CFTRtransporttotheapicalmembraneinCFcells.hAMSCs
showed a very faint signal related to CFTR (Figure 7(e)).
Thesedataconﬁrmcytoﬂuorimetricanalysisastotheplasma
membrane expression of CFTR in labelled hMSCs which
increases when Cocultured with CF cells.
4. Discussion
HumanMSCsarepluripotent stemcellsinitiallyidentiﬁedin
postnatal bone marrow (BM) [20], which is the most com-
mon source used in clinical settings [21]. However, the use of
BM has some limitations, including the low frequency of
MSCs and the invasive procedure for obtaining them. More-
over,theageanddiseasestatemayaﬀectthecollectionofsuf-
ﬁcient healthy autologous BM for transplantation [22–24].
Finally, expansion of autologous BM cells could represent a
cumbersome and low-yield approach. In the present study,
we directed our attention on a source, the amniotic mem-
brane,whichisrichinMSCs[25],iseasilyaccessibleandeth-
ically acceptable, since the term placenta is discarded after
delivery. hAMSCs have been shown to be superior in prolif-
eration and diﬀerentiation potential to BM cells [26]a n dt oJournal of Biomedicine and Biotechnology 11
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Figure 7: CFTR immunodetection by confocal analysis. Confocal scans are shown in the horizontal cross-section (xy) plane and vertical
cross-section (xz) plane. (a) CFBE41o- cells; (b) hAMSCs- CFBE 1:5 ratio; (c) hAMSCs- CFBE 1:10 ratio; (d) hAMSCs- CFBE 1:15 ratio;
(e) hAMSCs alone. The white arrows point to CM-DiI-labelled hAMSCs expressing CFTR on their membrane (green signal). Note in (d)
that hAMSCs harbour some CFTR-speciﬁc signal in discrete regions under the apical plasma membrane.
display diﬀerentiation potential towards mesoderm lineages
(osteogenic, chondrogenic, and adipogenic) similar to BM
cells [25–27]. Importantly, various studies have reported dif-
ferentiationofhAMSCstoectoderm(neural)[27,28],meso-
derm (skeletal muscle, cardiomyocytic, and endothelial) [26,
29–31], and endoderm (pancreatic) [32] lineages.
In the present study, we isolated and characterized
hAMSCsaccordingtopreviouslypublishedprotocols,thatis,
by removing the epithelial cells by enzymatic digestion and
obtaining the hAMSC suspension by collagenase and DNase
treatment [26, 27, 30, 33, 34]. hAMSCs show a higher proli-
ferativepotentialthanBMMSCs[26,35],and,inourculture
conditions, they reached a plateau after 21 days in culture,
similarlytowhathasbeenseeninapreviousstudy[26],while
others have observed a plateau already at day 11 [25]. hAM-
SCs displayed a ﬁbroblastic morphology and presented sur-
face markers expressed also by BM-MSCs and cells isolated
from both the amnion and other regions of the full-term
placenta such as CD29, CD44, CD105, CD73, CD90, and
vimentin and were negative for the hematopoietic markers
CD45 and CD34 [26, 27, 35–39]. They also displayed posi-
tivity for the epithelial markers CD49f and CK18; since these
markers are lost upon culture, they could represent a small
contamination by epithelial cells, which has been described
also previously [33, 40]. This hypothesis is corroborated by
CFTR mRNA expression in hAECs upon their isolation from
the placenta (as shown in Figure 6). Interestingly, it has been
observed that adherent cells obtained from human amniotic
membranes were comprised of both round-shaped epithelial
cells and spindle-shaped ﬁbroblast-like cells prior to the ﬁrst
passage, whereas the epithelial cells were rarely detected after
the third passage [37]. In alternative, this hybrid phenotype
of hAMSCs [41] is interpreted as a sign of pluripotency and
suggests that the amnion-derived cells had not completely
diﬀerentiatedintoepithelialormesenchymalcells[3].Never-
theless, as shown here, the amniotic cells derived from term
placenta seem to remain somewhat “plastic” and maintain
thecapabilitytodiﬀerentiateandcontributetocellsfromdif-
ferent germ layers. Mesodermal diﬀerentiation of MSC from
various sources was widely reported in the literature and is
considered one of the principal assay to prove “stemness” of
mesenchymalcells[20,22,29].Notdiﬀerentlyfromprevious
papers, hAMSCs isolated in our experiments were able to
diﬀerentiate into both adipocytes and osteocytes. In recent
years, the exploitation of adipose tissue or bone marrow-de-
rived MSC for hepatocyte diﬀerentiation and liver repair was
explored by many researchers [42–44] but, to the best of our
knowledge, only one previous study has demonstrated that
hAMSCscandiﬀerentiateintohepatocyte-likecells,although
only at gene-expression level [37].12 Journal of Biomedicine and Biotechnology
Because amniotic cells can diﬀerentiate into diﬀerent cell
types, we examined them with antibodies directed against
well-known surface markers characteristic of embryonic
stem cells. Amniotic cells express the stage-speciﬁc embry-
onic antigen SSEA-4 [45] although the relative proportion
of SSEA-4-positive cells in initial isolates is lower than that
observed with embryonic stem cells [46]. In addition to
characteristic stem cell surface markers, amniotic cells show
very low expression of Oct-4 and Nanog, transcription fac-
tors involved in regulating ES cells’ self-renewal and diﬀer-
entiation, as it has been previously shown for freshly isolated
MSCs obtained from bone marrow, adipose tissue, and heart
[47].Furtherstudiesareneededtounderstandwhetherthese
genes are regulated during the in vitro culture conditions, so
toidentifyregulatorypathwaysthatmimicinvivoactivation.
CF is a potential model disease for stem cell therapy be-
cause of the persistent lung inﬂammation that leads to dam-
age and remodeling and can promote engraftment of stem
cells [7]. A developing potential therapeutic approach for CF
and other lung diseases hasbeen stimulated byrecent reports
demonstrating that several cell populations derived from
adult bone marrow, from amniotic ﬂuid or from umbilical
cord blood, including MSCs, endothelial progenitor cells,
and circulating ﬁbrocytes, can localize to the lung and ac-
quire phenotypic and functional markers of mature lung-
speciﬁccells[10,11,48].TheresultspublishedbyWangetal.
[49] and Loi et al. [8] strongly suggest that the population of
BM cells relevant for repopulating the lung epithelium may
be found in the plastic adherent stromal cell compartment.
Besides the drawbacks presented by BM-MSCs discussed
above, amniotic ﬂuid contains a heterogeneous population
of cells from fetal origin [25], whereas MSCs could not be
reliably isolated from all term umbilical cordon blood sam-
ples [10, 50–52].
In the present study, we propose human placenta as an
ethical source of MSCs for CF therapy. The ﬁrst goal was to
investigate the CFTR expression in these cells. At the earliest
stages of human development, CFTR protein and function
have been detected in early blastocysts in the apical mem-
brane of trophectoderm cells, while its expression at mRNA
level has been shown in ﬁrst trimester placenta (8-week ges-
tation) [53]. However, no data are available concerning its
mRNA and protein levels in speciﬁc cell types of term pla-
centa. In this study, we show that a nested RT-PCR was nec-
essary for obtaining a detectable signal from freshly isolated
hAMSCs, indicating very low levels of CFTR mRNA in these
cells. We have recently shown that also hematopoietic stem/
progenitor cells display such low levels upon puriﬁcation
from the bone marrow [18]. The reason why CFTR must be
keptatlowexpressionlevelsinstem/progenitorcellcompart-
mentsisnotknownatthemoment.Althoughatthismoment
we do not know whether freshly isolated hAMSCs show
CFTR expression or the speciﬁc band by RT-PCR is given by
an epithelial contamination, CFTR mRNA was barely visible
at passages one and three. Confocal microscopy conﬁrmed
these results at the protein level. Notably, CFTR was reex-
pressed by hAMSCs upon Coculture with epithelial cells, as
demonstrated unequivocally by ﬂow cytometry and confocal
microscope analysis. At this stage, we do not know why the
lower the hAMSCs:CFBE41o- ratios the lower the CFTR ex-
pression in hAMSCs. It can be speculated that this eﬀect
might be due to cross-talk between amniotic and epithelial
cells, for which a critical number of hAMSCs are needed. In-
deed, in other Coculture systems, developed with MSCs and
chondrocytes, it has been shown universally that the more
chondrocytesthelowertheexpressionofextracellularmatrix
genes and functional properties of engineered cartilage [54,
55].
Also, the mechanism underlying this eﬀect is to be dis-
covered yet. However, indirect cocultures data give us an in-
dication that this eﬀect is primarily due to the contact be-
tween amnion MSCs and epithelial cells, and not to factors
acting by a paracrine manner. Lung morphogenesis is an
orchestrated molecular and cellular process controlled by
cellular interactions with growth factors and morphogenic
factors [56]. Since the cellular interactions between epithelial
and mesenchymal cells in monolayer Coculture are likely to
be bidirectional, a possible mode of action could be cross-
talkbetween cellsviagapjunctions, whichhasbeen observed
in vivo in the lung between transplanted MSCs and resident
epithelial cells [57]. Recently, it has been found that MSCs
couldbeinducedtodiﬀerentiateintocornealepithelium[58]
or endothelium [59] in Coculture condition, but not in the
indirect Coculture system where MSCs and endothelial cells
were cultured in separate inserts [59]. More importantly,
BM-MSCs acquired an airway epithelium phenotype when
Cocultured with respiratory epithelial cells and determined
a partial resumption of the chloride secretion defect in CF
epithelia [49]. Although we have not analyzed the correction
of the chloride transport defect in CFBE14o- monolayers by
hAMSCs, based on the work by Wang et al. [49], it can be
anticipated that we should see the same eﬀect on the basic
electrophysiological defect. Furthermore, since only 6–20%
of corrected cells are needed to revert the basic defect in
chloride secretion [60], our data showing that 33–50% of
hAMSCs acquired CFTR expression shed a positive light on
the use of amnion MSCs in the CF treatment.
5. Conclusions
Our data indicate hAMSCs as a novel, promising, readily
accessible, and ethically compatible source of pluripotent
cells that could be used in regenerative medicine. In this res-
pect, hAMSCs present promising features as indicated by
their expression of embryonic stem cell markers such as
SSEA4 and by their diﬀerentiation potential towards meso-
dermal and endodermal lineages.
Although CF is a clinically heterogeneous disease caused
by a defect in the CFTR gene aﬀecting multiple organ sys-
tems, major morbidity and mortality are given by the lung
disease; however, hepatobiliary complications of CF are in-
creasingly common and clinically relevant as the age of pa-
tients increases [61, 62]. This study shows the diﬀerentiative
potential of hAMSCs towards hepatocyte-like cells, which
might be useful in CF, and highlights the need for further
investigations to elucidate the mechanism mediating CFTR
expression in hAMSCs upon cell to-cell interactions.Journal of Biomedicine and Biotechnology 13
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